Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

7.14

Margin Of Safety %

32

Put/Call OI Ratio

0.62

EPS Next Q Diff

0.16

EPS Last/This Y

0.09

EPS This/Next Y

0.14

Price

15.75

Target Price

21.25

Analyst Recom

2.78

Performance Q

-12.26

Relative Volume

0.87

Beta

0.71

Ticker: OGN




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2024-12-19OGN14.430.661.0748609
2024-12-20OGN14.570.660.9248678
2024-12-23OGN14.690.680.3736467
2024-12-24OGN14.730.680.8337128
2024-12-26OGN14.950.680.3637483
2024-12-27OGN15.060.670.7337896
2024-12-30OGN14.650.671.7138237
2024-12-31OGN14.920.660.0938640
2025-01-02OGN14.970.571.4842746
2025-01-03OGN15.440.600.0843682
2025-01-06OGN15.50.570.2045287
2025-01-07OGN15.730.590.3244594
2025-01-08OGN16.020.591.0344861
2025-01-09OGN160.590.9344861
2025-01-10OGN15.850.590.0645116
2025-01-13OGN15.650.610.2344618
2025-01-14OGN15.820.601.3144958
2025-01-15OGN15.740.610.6745425
2025-01-16OGN16.180.620.2745693
2025-01-17OGN15.750.620.4846015
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2024-12-19OGN14.441.1- 4.10
2024-12-20OGN14.591.1- 4.10
2024-12-23OGN14.701.1- 4.10
2024-12-24OGN14.731.1- 4.10
2024-12-26OGN14.951.1- 4.10
2024-12-27OGN15.051.1- 4.10
2024-12-30OGN14.651.1- 4.10
2024-12-31OGN14.911.1- 4.10
2025-01-02OGN14.961.1- 4.10
2025-01-03OGN15.431.1- 4.10
2025-01-06OGN15.491.1- 4.10
2025-01-07OGN15.731.1- 4.10
2025-01-08OGN16.001.1- 4.10
2025-01-09OGN16.001.1- 4.10
2025-01-10OGN15.851.1- 4.10
2025-01-13OGN15.651.1- 4.10
2025-01-14OGN15.811.1- 4.10
2025-01-15OGN15.731.1- 4.10
2025-01-16OGN16.171.1- 4.10
2025-01-17OGN15.751.1- 4.10
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2024-12-19OGN0.000.835.32
2024-12-20OGN0.000.835.32
2024-12-23OGN0.000.865.32
2024-12-24OGN0.000.865.32
2024-12-26OGN0.000.865.94
2024-12-27OGN0.000.865.94
2024-12-30OGN0.000.815.94
2024-12-31OGN0.000.815.94
2025-01-02OGN0.000.815.94
2025-01-03OGN0.000.815.94
2025-01-06OGN0.000.815.94
2025-01-07OGN0.000.815.94
2025-01-08OGN0.000.815.94
2025-01-09OGN0.000.815.94
2025-01-10OGN0.000.815.94
2025-01-13OGN0.001.087.14
2025-01-14OGN0.001.087.14
2025-01-15OGN0.001.087.14
2025-01-16OGN0.001.087.14
2025-01-17OGN0.001.087.14
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

0.87

Avg. EPS Est. Current Quarter

0.89

Avg. EPS Est. Next Quarter

1.03

Insider Transactions

Institutional Transactions

1.08

Beta

0.71

Average Sales Estimate Current Quarter

1590

Average Sales Estimate Next Quarter

1604

Fair Value

20.73

Quality Score

87

Growth Score

71

Sentiment Score

68

Actual DrawDown %

60.1

Max Drawdown 5-Year %

Target Price

21.25

P/E

3.12

Forward P/E

3.81

PEG

0.66

P/S

0.63

P/B

8.22

P/Free Cash Flow

5.43

EPS

5.04

Average EPS Est. Cur. Y​

4.1

EPS Next Y. (Est.)

4.24

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

20.3

Relative Volume

0.87

Return on Equity vs Sector %

244.8

Return on Equity vs Industry %

237.2

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.24

EBIT Estimation

Organon & Co.
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 10000
Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.
stock quote shares OGN – Organon & Co. Stock Price stock today
news today OGN – Organon & Co. stock forecast ,stock prediction 2023 2024 2025
marketwatch OGN – Organon & Co. yahoo finance google finance
stock history OGN – Organon & Co. invest stock market
stock prices OGN premarket after hours
ticker OGN fair value insiders trading